Actin Retrograde Flow Regulated by the Wiskott-Aldrich Syndrome Protein Drives the Natural Killer Cell Response.
ARF
SHP-1
WASp
mechanotransduction
myosin IIA
natural killer cells
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Aug 2022
02 Aug 2022
Historique:
received:
21
07
2022
accepted:
26
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Understanding the crosstalk between natural killer (NK) cells and the tumor microenvironment (TME) has enhanced the potential of exploiting the interplay between activation and inhibition of NK cells for immunotherapy. This interaction is crucial for understanding how tumor cells escape NK cell immune surveillance. NK cell dysfunction is regulated by two molecular mechanisms, downregulated activating receptor ligand expression on the tumor cells, and upregulated inhibitory signals delivered to NK cells. Recent studies demonstrated the role of mechanotransduction in modulating NK cell responses in the TME. The immunological synapse represents a functional interface between the NK cell and its target, regulated by Actin Retrograde Flow (ARF), which drives the adhesion molecules and receptors toward the central zone of the immunological synapse (IS). Here, we further characterize the role of ARF in controlling the immune response of NK cells, using CRISPR/cas9-mediated Wiskott-Aldrich Syndrome protein (WASp) gene silencing of NK cells. We demonstrate that WASp regulates ARF velocity, affecting the conformation and function of the key NK inhibitory regulator, SH2-domain containing protein tyrosine phosphatase-1 (SHP-1), and consequently, the NK cell response. Our results demonstrate the potential of modulating the biophysical and intracellular regulation of NK activation as a promising approach for improving immunotherapy.
Identifiants
pubmed: 35954420
pii: cancers14153756
doi: 10.3390/cancers14153756
pmc: PMC9367451
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : United States-Israel Binational Science Foundation
ID : 2019211
Références
Clin Genet. 2008 Jul;74(1):68-74
pubmed: 18479478
Blood. 2011 Nov 24;118(22):5862-71
pubmed: 22123909
Blood. 2006 Feb 1;107(3):994-1002
pubmed: 16204312
J Leukoc Biol. 2019 Jun;105(6):1261-1273
pubmed: 30707462
J Immunol. 2005 Jul 15;175(2):749-54
pubmed: 16002670
Immunity. 2014 Feb 20;40(2):225-34
pubmed: 24440149
Curr Protoc Immunol. 2010 Aug;Chapter 11:Unit 11.9B
pubmed: 20814939
J Exp Med. 2004 Sep 20;200(6):817-23
pubmed: 15365099
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
Sci Signal. 2016 May 24;9(429):ra54
pubmed: 27221712
Front Immunol. 2020 Feb 21;11:275
pubmed: 32153582
Int Rev Cell Mol Biol. 2020;356:131-196
pubmed: 33066873
Curr Protoc Immunol. 2011 Apr;Chapter 11:Unit 11.7
pubmed: 21462163
EMBO Mol Med. 2022 Jan 11;14(1):e14073
pubmed: 34725941
Immunity. 2008 Oct 17;29(4):578-88
pubmed: 18835194
Immunity. 2001 Mar;14(3):315-29
pubmed: 11290340
Blood. 2010 Apr 8;115(14):2818-26
pubmed: 20130240
PLoS Biol. 2009 Jul;7(7):e1000159
pubmed: 19636352
Sci Signal. 2014 Jun 24;7(331):ra60
pubmed: 24962707
J Clin Invest. 2011 Apr;121(4):1535-48
pubmed: 21383498
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33621210
Blood. 2006 Jan 1;107(1):159-66
pubmed: 16150947
Cancer Discov. 2014 May;4(5):522-6
pubmed: 24795012
J Immunol. 2005 Mar 1;174(5):2602-11
pubmed: 15728466
J Immunol. 2006 Aug 15;177(4):2349-55
pubmed: 16887996
Dis Model Mech. 2015 Dec;8(12):1495-515
pubmed: 26542704
Blood. 2004 Jul 15;104(2):436-43
pubmed: 15001467
EMBO J. 2018 Mar 1;37(5):
pubmed: 29449322
Immunol Cell Biol. 2014 Mar;92(3):245-55
pubmed: 24445602
J Cell Biol. 2012 Jun 11;197(6):775-87
pubmed: 22665519
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11351-6
pubmed: 12177428
Biochim Biophys Acta. 2014 Feb;1838(2):557-68
pubmed: 23860253
Elife. 2022 Mar 08;11:
pubmed: 35258455
PLoS Biol. 2011 Sep;9(9):e1001152
pubmed: 21931537
J Exp Med. 2007 Oct 1;204(10):2285-91
pubmed: 17875677
Curr Opin Immunol. 2003 Jun;15(3):308-14
pubmed: 12787756
Immunol Rev. 2013 Nov;256(1):10-29
pubmed: 24117810
Sci Signal. 2016 May 24;9(429):fs8
pubmed: 27221707
J Immunol. 2009 Jun 1;182(11):6969-84
pubmed: 19454694
Crit Rev Oncog. 2014;19(1-2):91-105
pubmed: 24941376
Mol Biol Cell. 2015 Feb 15;26(4):685-95
pubmed: 25518938
Int J Mol Sci. 2012;13(6):7629-47
pubmed: 22837718
Immunity. 2006 Aug;25(2):331-42
pubmed: 16901727
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10346-10351
pubmed: 16801532
Biophys J. 2013 Jul 16;105(2):481-93
pubmed: 23870269
Nature. 2001 Feb 22;409(6823):1055-60
pubmed: 11234016
Front Immunol. 2018 Sep 19;9:2110
pubmed: 30283450
J Exp Med. 2014 Jun 30;211(7):1289-96
pubmed: 24958849
Mol Biol Cell. 2012 Mar;23(5):834-52
pubmed: 22219382
Front Cell Dev Biol. 2021 Feb 01;9:609532
pubmed: 33598461
Dev Cell. 2022 Jan 10;57(1):47-62.e9
pubmed: 34919802
Curr Biol. 2018 Feb 19;28(4):489-502.e9
pubmed: 29398219
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20296-301
pubmed: 18077330
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Leukoc Biol. 2014 Nov;96(5):713-27
pubmed: 25210148
Eur J Immunol. 2014 Apr;44(4):1039-45
pubmed: 24338698
Cell Signal. 2004 Jan;16(1):1-11
pubmed: 14607270
J Cell Biol. 2006 Apr 10;173(1):121-32
pubmed: 16606694
J Biol Chem. 2014 Dec 12;289(50):34503-19
pubmed: 25342748
Mol Cell Biol. 2003 Sep;23(17):6291-9
pubmed: 12917349